Oryzon Genomics's Total Assets for the quarter that ended in Mar. 2026 was MXN2,938.07 Mil.
During the past 12 months, Oryzon Genomics's average Total Assets Growth Rate was 14.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 11.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 16.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 19.80% per year.
During the past 12 years, Oryzon Genomics's highest 3-Year average Total Assets Growth Rate was 28.10%. The lowest was 5.90%. And the median was 18.00%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Oryzon Genomics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Oryzon Genomics Total Assets Related Terms
Oryzon Genomics Total Assets Historical Data
* Premium members only.
The historical data trend for Oryzon Genomics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Oryzon Genomics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oryzon Genomics (MEX:ORYN) has a Total Assets of MXN2,938.07 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Total Assets too high?
Oryzon Genomics' current Total Assets is MXN2,938.07 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Total Assets compare to VRTX and REGN?
Oryzon Genomics' Total Assets of MXN2,938.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Total Assets is MXN2,938.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (MEX:ORYN) has a current Total Assets of MXN2,938.07 Mil. The current Total Assets is MXN2,938.07 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Oryzon Genomics (MEX:ORYN), the current Total Assets is MXN2,938.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score
Get the complete analysis for MEX:ORYN
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ORYN has been successfully added to your 
